(E)-N-(pyridin-4-ylmethyl)-3-(3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-enamide
C21H17N5O — CID 155520850
Data last refreshed: (MolForge compound catalog, from PubChem)
About (E)-N-(pyridin-4-ylmethyl)-3-(3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-enamide
(E)-N-(pyridin-4-ylmethyl)-3-(3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-enamide (PubChem CID 155520850) has the molecular formula C21H17N5O and a molecular weight of 355.40 g/mol. Its IUPAC name is (E)-N-(pyridin-4-ylmethyl)-3-(3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-enamide.
Molecular Properties
| Compound Name | (E)-N-(pyridin-4-ylmethyl)-3-(3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-enamide |
|---|---|
| PubChem CID | 155520850 |
| Molecular Formula | C21H17N5O |
| Molecular Weight | 355.40 g/mol |
| Exact Mass | 355.14 |
| IUPAC Name | (E)-N-(pyridin-4-ylmethyl)-3-(3-pyridin-4-yl-1H-pyrrolo[2,3-b]pyridin-5-yl)prop-2-enamide |
| SMILES | O=C(/C=C/c1cnc2[nH]cc(-c3ccncc3)c2c1)NCc1ccncc1 |
| InChI | InChI=1S/C21H17N5O/c27-20(24-12-15-3-7-22-8-4-15)2-1-16-11-18-19(14-26-21(18)25-13-16)17-5-9-23-10-6-17/h1-11,13-14H,12H2,(H,24,27)(H,25,26)/b2-1+ |
| InChIKey | ICJNSFYIUHQCNU-OWOJBTEDSA-N |
| XLogP | 3.35 |
| TPSA | 83.56 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 27 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 355.40 |
| LogP ≤ 5 | 3.35 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 155520850 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.